Analysis of the relationship between resistin with prognosis, cell migration, and p38 and ERK1/2 activation in breast cancer

被引:0
|
作者
Cuachirria-Espinoza, Reyna L. [1 ]
Garcia-Miranda, Alin [1 ]
Hernandez-Barragan, Rafael [1 ]
Nava-Tapia, Dania A. [1 ]
Olea-Flores, Monserrat [1 ]
Navarro-Tito, Napoleon [1 ]
机构
[1] Univ Autonoma Guerrero, Fac Ciencias Quim Biol, Lab Biol Celular Canc, Ave Lazaro Cardenas S-N, Chilpancingo 39090, Gro, Mexico
关键词
Resistin; Prognosis; Cell migration; p38MAPK; ERK1/2; Breast cancer; EXPRESSION; SUBTYPES; TISSUE;
D O I
10.1016/j.biochi.2024.10.001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Obesity increases the risk and mortality of breast cancer through dysregulated secretion of proinflammatory cytokines and tumor adipokines that induce an inflammatory breast microenvironment. Resistin is an adipokine secreted by adipocytes, immune cells, and predominantly macrophages, which contributes to cancer progression, but its molecular mechanism in cancer is not completely described. In this study, we analyzed the relationship of resistin on breast cancer prognosis and tumor progression and the effect in vitro of resistin on p38 and ERK1/2 activation in breast cancer cell lines. By bioinformatic analysis, we found that resistin is overexpressed in the basal subtype triple-negative breast cancer and is related to poor prognosis. In addition, we demonstrated a positive correlation between RETN and MAPK3 expression in basal triple-negative breast cancer. Importantly, we found amplifications of the RETN gene in at least 20 % of metastatic samples from patients with breast cancer. Most samples with RETN amplifications metastasized to bone and showed high expression of IL-8 (CXCL8) and IL-6 (IL6). Finally, resistin could be considered a prognostic marker for basal triple-negative breast cancer, and we also proposed the possibility that resistin-induced cell migration involves the activation of MAPK in breast cancer cells. (c) 2024 Elsevier B.V. and Soci & eacute;t & eacute; Fran & ccedil;aise de Biochimie et Biologie Mol & eacute;culaire (SFBBM). All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页码:19 / 29
页数:11
相关论文
共 50 条
  • [41] NFATC1 promotes cell growth and tumorigenesis in ovarian cancer up-regulating c-Myc through ERK1/2/p38 MAPK signal pathway
    Xu, Wenwen
    Gu, Junjie
    Ren, Qingling
    Shi, Yanqiu
    Xia, Qinhua
    Wang, Jing
    Wang, Suli
    Wang, Yingchun
    Wang, Jinhua
    TUMOR BIOLOGY, 2016, 37 (04) : 4493 - 4500
  • [42] AKR1B10 promotes breast cancer cell migration and invasion via activation of ERK signaling
    Li, Jia
    Guo, Yuanwei
    Duan, Lili
    Hu, Xinglin
    Zhang, Xi
    Hu, Jian
    Huang, Li
    He, Rongzhang
    Hu, Zheng
    Luo, Weihao
    Tan, Tan
    Huang, Renbin
    Liao, Duanfang
    Zhu, Yuan-Shan
    Luo, Di-Xian
    ONCOTARGET, 2017, 8 (20) : 33694 - 33703
  • [43] ATP promotes resident CD34+ cell migration mainly through P2Y2-Stim1-ERK/p38 pathway
    Ma, Ying
    Han, Chuting
    Xie, Cheng
    Dang, Qingya
    Yang, Liju
    Li, Yuan
    Zhang, Min
    Cheng, Jun
    Yang, Yan
    Xu, Qingbo
    Li, Pengyun
    AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2023, 325 (05): : C1228 - C1243
  • [44] Insulin-like growth factors inhibit dendritic cell-mediated anti-tumor immunity through regulating ERK1/2 phosphorylation and p38 dephosphorylation
    Huang, Ching-Ting
    Chang, Ming-Cheng
    Chen, Yu-Li
    Chen, Tsung-Ching
    Chen, Chi-An
    Cheng, Wen-Fang
    CANCER LETTERS, 2015, 359 (01) : 117 - 126
  • [45] Evidences for involvement of estrogen receptor induced ERK1/2 activation in ovarian cancer cell proliferation by Cadmium Chloride
    Ataei, Negar
    Aghaei, Mahmoud
    Panjehpour, Mojtaba
    TOXICOLOGY IN VITRO, 2019, 56 : 184 - 193
  • [46] Modulation of MAPK ERK1 and ERK2 in VDR-positive and -negative breast cancer cell lines
    Cordes, T.
    Diesing, D.
    Becker, S.
    Diedrich, K.
    Reichrath, J.
    Friedrich, M.
    ANTICANCER RESEARCH, 2006, 26 (4A) : 2749 - 2753
  • [47] Design and synthesis of potent 1,2,4-trisubstituted imidazolinone derivatives with dual p38αMAPK and ERK1/2 inhibitory activity
    Awadallah, Fadi M.
    Abou-Seri, Sahar M.
    Abdulla, Mohamed M.
    Georgey, Hanan H.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2015, 94 : 397 - 404
  • [48] IL-1β Upregulates IL-8 Production in Human Müller Cells Through Activation of the p38 MAPK and ERK1/2 Signaling Pathways
    Xiufen Liu
    Fei Ye
    Huabao Xiong
    Danning Hu
    G. Astrid Limb
    Tian Xie
    Liang Peng
    Wei Yang
    Yabin Sun
    Mingming Zhou
    E Song
    David Y. Zhang
    Inflammation, 2014, 37 : 1486 - 1495
  • [49] Indirubin-3′-monoxime inhibits autophosphorylation of FGFR1 and stimulates ERK1/2 activity via p38 MAPK
    Y Zhen
    V Sørensen
    Y Jin
    Z Suo
    A Więdłocha
    Oncogene, 2007, 26 : 6372 - 6385
  • [50] Knockdown of NUPR1 inhibits the proliferation of glioblastoma cells via ERK1/2, p38 MAPK and caspase-3
    Li, Jun
    Ren, Siyang
    Liu, Yongjian
    Lian, Zhigang
    Dong, Bin
    Yao, Yiqun
    Xu, Yinghui
    JOURNAL OF NEURO-ONCOLOGY, 2017, 132 (01) : 15 - 26